Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
Go back to Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer| Textainer Group Holdings limited (NASDAQ: GH) | Delayed: 177.94 -5.16 (2.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $183.10 | 52 Week High | $5.84 | |||
| Open | $183.00 | 52 Week Low | $5.49 | |||
| Day High | $183.50 | P/E | N/A | |||
| Day Low | $175.62 | EPS | $0.00 | |||
| Volume | 712,190 | |||||
